SCHEMBL3301585

SCHEMBL3301585

O=S(=O)(c1ccc(Nc2nccc(Nc3ccc(F)cc3)n2)cc1)N1CCC(C(O)c2cccnc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.47
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP11B2 P19099 2/20 0.45
CYP11B1 P15538 1/20 0.45
NAMPT P43490 4/20 0.43
MERTK Q12866 1/20 0.42
CA2 P00918 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
IDH1 O75874 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HTT P42858 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK8 P45983 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13392203 1.00 RAB9A (0.47) RAB9AMAPTLMNAMEN1NPC1
SCHEMBL3302531 0.92 RAB9A (0.46) RAB9AMAPTLMNAMEN1NPC1
SCHEMBL13392300 0.92 IKBKB (0.49) RAB9AMAPTCYP11B2CYP11B1NAMPT
SCHEMBL3306811 0.92 IKBKB (0.49) RAB9AMAPTCYP11B2CYP11B1NAMPT
SCHEMBL13392326 0.91 MAPT (0.50) RAB9AMAPTLMNAMEN1NPC1
SCHEMBL13392293 0.90 IKBKB (0.42) RAB9AMAPTCYP11B2CYP11B1NAMPT
SCHEMBL3300337 0.90 IKBKB (0.42) RAB9AMAPTCYP11B2CYP11B1NAMPT
SCHEMBL14095781 0.90 RAB9A (0.45) RAB9AMAPTLMNAMEN1NPC1
SCHEMBL13392093 0.87 CYP11B2 (0.49) RAB9AMAPTLMNAMEN1NPC1
SCHEMBL3300456 0.87 CYP11B2 (0.49) RAB9AMAPTLMNAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE RAB9A 2993/4885MAPT 3372/4885LMNA 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.